This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: April 2, 2008
Last updated: November 16, 2016
Last verified: November 2016
The purpose of this study is to investigate the effects of iron chelation using deferasirox in patients who show signs of iron overload after an allogeneic stem cell transplantation The iron overload must be due to blood transfusions.

Condition Intervention Phase
Iron Overload Drug: Deferasirox Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/d) in Patients Three to Six Months After Allogeneic Hematopoietic Cell Transplantation in Whom Iron Overload is Present

Resource links provided by NLM:

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • To assess iron chelation by comparing serum ferritin values at baseline vs. 52 weeks of treatment with deferasirox [ Time Frame: 52 weeks ]

Secondary Outcome Measures:
  • To evaluate the relationship between serum ferritin, transferrin (TRF) and transferrin saturation during the whole study. [ Time Frame: 52 weeks ]

Enrollment: 75
Study Start Date: February 2008
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: deferasirox Drug: Deferasirox
Other Name: ICL670


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Transfusional iron overload three to six months after HCT with no evidence of active inflammation
  2. History of at least 20 units of red blood cell transfusions or 100mL/kg of prepacked red blood cells (PRBCs).
  3. Patients of either gender and age ≥ 18 years.
  4. Female patients who have reached menarche and who are sexually active must use double-barrier contraception, oral contraceptive plus barrier contraception , or must have undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation or be postmenopausal defined by amenorrhea for at least 12 months.

Exclusion criteria:

  1. Non-transfusion related iron overload
  2. Active malignancy
  3. Known active viral hepatitis or known HIV positiveness
  4. Mean levels of alanine aminotransferase (ALT) > 5x ULN
  5. Treatment with any iron chelator after transplantation
  6. Uncontrolled systemic hypertension
  7. Serum creatinine > 1.5 ULN and/or serum creatinine clearance < 60 ml/min
  8. History of nephrotic syndrome.
  9. Previous history of clinically relevant ocular or auditory toxicity related to iron chelation.
  10. Systemic diseases (cardiovascular, renal, hepatic, etc.) which would prevent the patient from undergoing study treatment
  11. Pregnant or breast feeding patients.

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00654589

Novartis Investigative Site
Leipzig, Germany
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmeceuticals
  More Information

Additional Information:
Responsible Party: Novartis Pharmaceuticals Identifier: NCT00654589     History of Changes
Other Study ID Numbers: CICL670ADE02
Study First Received: April 2, 2008
Last Updated: November 16, 2016

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Hematopoietic stem cell transplantation
iron overload
serum ferritin
transfusional hemosiderosis
blood transfusions
iron chelation
3-6 months
allogeneic hematopoietic stem cell transplantation

Additional relevant MeSH terms:
Iron Overload
Iron Metabolism Disorders
Metabolic Diseases
Trace Elements
Growth Substances
Physiological Effects of Drugs
Iron Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action processed this record on August 17, 2017